Information Provided By:
Fly News Breaks for May 12, 2016
MRTX
May 12, 2016 | 06:21 EDT
Piper Jaffray analyst Steven Breazzano assumed coverage of Mirati Therapeutics with a Neutral rating and $17 price target.
News For MRTX From the Last 2 Days
There are no results for your query MRTX